To explore new targets for hepatoma research, we used a surface display library to screen novel tumor cell-specific peptides. The bacterial FliTrx system was screened with living normal liver cell line L02 and hepatoma cell line HepG2 successively to search for hepatoma-specific peptides. Three clones (Hep1, Hep2, and Hep3) were identified to be specific to HepG2 compared with L02 and other cancer cell lines. Three-dimensional structural prediction proved that peptides inserted into the active site of Escherichia coli thioredoxin 
men and 3.5% among women) [1, 2] . The main obstacles to improving control and treatment of hepatoma are the lack of biomarkers for early diagnosis [3] and selective delivery of chemotherapeutic drugs into the tumor cells in vivo [4] .
Phage display technology is a very powerful tool for the identification of critical amino acids responsible for protein-protein interaction and the discovery of new therapeutic targets [5, 6] . In the current study, we chose a bacterial peptide library, the FliTrx Escherichia coli thioredoxin (TrxA) scaffold random peptide library, which has been widely used to identify conformationally constrained dodecamer peptide sequences specifically recognized by soluble proteins, such as monoclonal antibodies [7, 8] . The FliTrx peptide library has an estimated diversity of 1.77×10 8 different random dodecamer loop sequences and does not contain any predefined structural motif. Thus, novel peptide sequences could be identified in this library that mimic the functions of protein domains found in nature [9] . In this flagella display library, peptides are directly displayed on the surface of E. coli fused with two proteins, the major bacterial flagellar protein (FliC) and TrxA. Various dodecapeptides are inserted within the active loop of TrxA, and the fusion protein forms a stable protrusion from the bacterial cell surface with the help of bacterial flagella [10, 11] . We wanted to identify FliTrx peptides specifically targeting tumor cells, not only to investigate target molecules, but also to deliver drugs into malignant tissues.
We identified three FliTrx peptides from the bacterial random library that are specific for hepatoma cell line HepG2 and do not bind to other cancer cell lines or normal liver cells. Results of structure prediction suggested that TrxA-peptide fusion proteins based on the TrxA active site might be more valuable than linear peptides themselves. Immune blotting results further proved that FliC/TrxA-peptide fusion proteins could be used to detect HepG2 cells and indicate a novel target molecule on these cells.
Materials and Methods

Cell culture
Human hepatoma cell line HepG2 and human liver cell line L02 (both cell lines were maintained in our laboratory) were cultured in RPMI 1640 (Gibco, Carlsbad, USA) supplemented with 10% (V/V) fetal bovine serum (Gibco) at 37 ºC in a 5% CO 2 incubator.
Selection of HepG2 cell-binding peptides
The FliTrx random peptide display library (Invitrogen, Carlsbad, USA) containing 1.77×10 8 primary clones was used to identify specific HepG2 cell-binding peptides incorporating negative selection using the normal liver cell line L02.
Bacteria were treated according to the manufacturer's instructions. The bacterial cells were diluted 10-fold in IMC medium (1× M9 salts, 0.2% casamino acids, 0.5% glucose, 1 mM MgCl 2 ) (Invitrogen) with 100 μg/ml ampicillin and cultured with shaking (225−250 rpm) at 25 ºC for 15 h.
The expression of the bacteria was induced by adding 3 ml of the overnight culture (approximately 1×10 10 cells) to 50 ml IMC medium containing 100 μg/ml ampicillin and 100 μg/ml tryptophan (Invitrogen) and the mixture was cultured with shaking for 6 h. Biopanning was carried out after induction of the bacterial library with tryptophan, which activated the transcription of the FliC/TrxA peptide fusion proteins.
A confluent dish with L02 cells was first blocked with IMC medium containing 1% bovine serum albumin (BSA) and 1% α-methyl mannoside (Sigma-Aldrich, St. Louis, USA) at 37 ºC for 1 h. Blocked cells were incubated with 10 ml induced bacterial suspension in IMC medium containing 1% BSA and 1% α-methyl mannoside at room temperature for 1 h. Unbound bacteria were transferred and incubated in another dish with blocked L02 cells at room temperature for 1 h. Then the unbound bacteria were transferred to the blocked HepG2 cells and incubated for another 1 h. Dishes with HepG2 cells were washed with IMC medium containing 1% α-methyl mannoside for 5 min and the wash was repeated four more times. Binding bacteria were obtained by stirring in a vortex for 30 s and subsequently amplified in IMC medium containing ampicillin (100 μg/ml) overnight for the next selection round. Recovered bacteria were counted by plating on RMG plates (1× M9 salts, 2% casamino acids, 0.5% glucose, 1 mM MgCl 2 , and 1.5% agar) (Invitrogen) supplemented with 100 μg/ml ampicillin. After five rounds of selection, individual clones were isolated and analyzed.
Clone polymerase chain reaction (PCR)
Individual clones were picked and lysed in 20 μl of 0.1% Triton X-100 and the lysate was used as a template. Reactions were carried out with FliTrx forward sequencing primer (5'-ATTCACCTGACTGACGAC-3'), FliTrx reverse sequencing primer (5'-CCCTGATATTCGTCAGCG-3') (synthesized by BioAsia, Shanghai, China), and Taq DNA polymerase (MBI Fermentas, St. Leon-Roth, Germany) in a volume of 20 μl for 2 min predenaturing at 94 ºC and 30 cycles of 1 min denaturing at 94 ºC, 1 min annealing at 55 ºC, and 1 min extension at 72 ºC. PCR products were analyzed by electrophoresis on 1% agarose gel. Clones containing inserts of 170 bp were selected for further analysis.
Flow cytometry
Individual clones were further screened for binding with HepG2 by flow cytometry, using L02 as negative control. Cells (1×10 5 cells/well) were removed from the dish with trypsin, washed once with phosphate-buffered saline (PBS)/1% BSA, and incubated with 50 μl induced bacteria (10 12 c.f.u./ml in PBS/1% BSA and 1% α-methyl mannoside) for 1 h on ice. Cells were washed twice with PBS/1% BSA and incubated with mouse Anti-Thio antibody (1:500 diluted) (TrxA; Invitrogen) for 30 min on ice. Cells were washed twice with PBS/1% BSA and incubated with fluorescein-isothiocyanate-conjugated anti-mouse immunoglobulin G (1:500 diluted) (Invitrogen) for 30 min on ice. Then the cells were washed twice with PBS/1% BSA and analyzed using FACSCalibur (Becton Dickinson, Oxford, UK). Clones that only bound HepG2, not L02, were selected for sequencing.
DNA sequencing and homology
Individual clones were isolated and sequenced by BioAsia (Shanghai) with forward sequencing primer 5'-ATTCACC-TGACTGACGAC-3' and reverse sequencing primer 5'-CCCTGATATTCGTCAGCG-3'. Sequences of dodecapeptides were submitted to the PubMed (http://www.ncbi. nlm.nih.gov/blast/Blast.cgi), SwissProt (http://expasy.org/ tools/blast/), and European Molecular Biology Laboratory (EMBL) (http://www.ebi.ac.uk/blast2/index.html) databases for homology analysis.
Characterization of specificity with flow cytometry
To characterize specificity, individual clones from the last screening round were analyzed using flow cytometry for binding with the following cancer cell lines: SLC (squamous lung carcinoma), MKN28 (gastric adenocarcinoma), K562 (chronic myelogenous leukemia), HeLa (cervix adenocarcinoma), MCF7 (mammary gland adenocarcinoma), HL60 (peripheral blood acute promyelocytic leukemia), and SMMC7721 (hepatocellular carcinoma). Similar techniques were used as above described.
Structure prediction
The sequences of selected peptides were analyzed with ExPASy proteomics and sequence analysis tools (http:// expasy.org/tools/). Secondary structure prediction was carried out by AGADIR (http://www.embl-heidelberg.de/ Services/serrano/agadir/agadir-start.html). Information on TrxA-peptide fusion proteins was sent to the 3D-JIGSAW c o mp a r a t i v e mo d e l i n g s e r v e r ( h t t p : / / b m m. cancerresearchuk.org/~3djigsaw/). VMD 1.8.5 (http:// www.ks.uiuc.edu/Research/vmd/vmd-1.8.5/) was used to display and analyze the results of the modeling of fusion regions.
Expression analysis of FliC/TrxA-peptide fusion protein and Western blot analysis
After being induced with 100 μg/ml tryptophan under optimized conditions for 6 h, the cultured bacteria were collected and the flagellin extracted as described by Ibrahim et al [12] , with some modifications. Briefly, the flagellin protein was extracted by exposure of the bacterial cells to 1 N hydrochloric acid at pH 2.0 for 20 min. Cellular debris was then separated by centrifugation at 1500 g for 15 min and the flagellin protein in the supernatant was collected. The pH of this supernatant solution was adjusted to 7.2 with 1 N sodium hydroxide before incubation with the polyvinylidene fluoride membrane.
HepG2, L02, and SLC cells were lysed in the sodium dodecyl sulfate sample buffer; proteins were separated on 8 % polya crylami de gels and tra nsferred to polyvinylidene fluoride membranes. Blots were incubated with 10 μg/ml FliC/TrxA-peptide fusion proteins (supernatant as mentioned above in PBS/0.2% Tween-20/5% skimmed milk) overnight at 4 ºC and washed with PBS/0.2% Tween-20. Membranes were detected using mouse Anti-Thio antibody (1:5000 diluted) and horseradish peroxidase-conjugated goat anti-mouse immunoglobulin G (1:2000 diluted). The final detection method is to add the horseradish peroxidase substrate solution containing DAB (3,3'-diaminobenzidine) (1.5 mg/ml) and watch for the appearance of coloured band on the nitrocellulose.
Results
Bioscreening
HepG2 binding-specific peptides were screened from the FliTrx random peptide library containing 1.77×10 8 primary clones. Induced bacterial display peptides were counter selected with normal liver cell line L02 to deplete healthy tissue-binding peptides. After incubation with L02 cells, unbound bacteria were obtained and panned with HepG2 cells. Five rounds of selection were carried out and the efficiency of selection was monitored by comparing the number of recovered bacteria in each round. An ever-increasing ratio of output/input ( 
Table 1 Recovery rate (output/input) of peptides during biopanning
After five rounds of biopanning, the ratio of output/input increased from 1.2×10 −6 to 4.8×10 −5 . The specific clones were successfully enriched during subtract bioscreening.
After five subtract-screening rounds, 700 clones were picked from the recovered bacteria in the last round for bacterial PCR to select clones containing whole fusion were selected for further investigation. Each of the clones and the corresponding exogenous sequence was given a sequential name from 1 to 200.
Confirmation of in vitro binding by flow cytometry
The binding ability of individual clones was verified by flow cytometry. To identify the specificity of selected clones for HepG2, the cell line L02 served as the control. Ten of the 200 peptides had clearly higher binding activity with HepG2 than with L02 (Fig. 2) . They were chosen to be sequenced. 
Sequence and homology analysis
Among the 10 selected clones, seven peptide sequences were identified due to repeated events ( Table 2) . Three clones, 11, 16, and 76, included the same dodecamer peptide sequence. Two clones, 34 and 60, were totally repeated sequences. Analysis of the amino acid sequences suggested that individual clones might share some consensus groups at an identical position, such as VA, EL, RI, AP, S-S, L-E, and W-E. In other words, there were some high-frequency amino acids. But these sequences were different from hepatocellular antigens or any other peptide or protein sequence available, as confirmed by BLAST in various protein databases such as SwissProt, PubMed, and the EMBL databases.
Characterization of specificity of peptides
Additional flow cytometry analysis was carried out to further determine the binding specificity of these seven peptides with tumor cell lines SLC, MKN28, K562, Hela, MCF7, and HL60. Three clones (11, 12 , and 34) showed obviously lower binding activity with other tumor cell lines than with HepG2 (Fig. 3) . We named these three peptides Hep1 (11), Hep2 (12), and Hep3 (34). Furthermore, we identified their binding specificity with hepatocellular carcinoma cell SMMC7721. Results showed that they could also bind to SMMC7221 cells, but the affinity was significantly lower compared with HepG2 (Fig. 4) .
Prediction of the structure of TrxA-peptide fusion protein
The amino acid sequences of Hep1, Hep2, and Hep3 were submitted to AGADIR and the results revealed that both Hep1 and Hep2 peptides had a very high helical potential [ Fig. 5(A−C) ]. This, in turn, implies that the dodecamer peptides might adopt a coiled-coil structure. As Hep3 peptide showed a very low helical potential, it was selected as a control for further structural and recognition The AGADIR prediction is expressed as helicity per residue along the peptide sequence. Three-dimensional structural models of TrxA-peptide fusion proteins TrxA-Hep1 (D), TrxA-Hep2 (E), and TrxA-Hep3 (F), developed by the 3D-JIGSAW server (http://bmm.cancerresearchuk.org/~3djigsaw/). The extended peptides are circled in the models.
investigation.
As dodecapeptides were inserted within the active loop of TrxA, we submitted the sequences of TrxA-peptide fusion proteins to the 3D-JIGSAW server to further develop the TrxA-peptide structural model. The overall structure is shown in Fig. 5(D,E) . The fusion protein consisted of two regions; TrxA had a central pleated β-sheet with five parallel and antiparallel β-strands, surrounded by three α-helices. Dodecapeptides formed a stable protrusion from the active site of TrxA, located at the beginning of a long α-helix. Hep1 formed a big loop [ Fig. 5(D) ], Hep2 was displayed as a β-sheet combined with one β-fold of TrxA overhanging from the TrxA region [ Fig. 5(E) ], and Hep3 stuck out from the TrxA region [ Fig. 5(F) ], forming two β-sheets by itself. The model showed that even Hep3 might not be a simple linear structure in the fusion protein.
Comparison with the secondary structure analysis showed that only the structure of Hep3 in the fusion protein was affected by TrxA. Hep1 and Hep2 were also constrained by TrxA, but the tertiary structure was similar to the secondary structure and not influenced by the fusion protein.
Identification of a novel target on HepG2 cells
The flagellin protein was extracted for Western blot assay. The Western blot analysis revealed that: (1) FliC/TrxApeptide fusion proteins were approximately 65 kDa; (2) no binding occured on L02 cell lysate or SLC cell lysate with FliC/TrxA-peptide fusion proteins; and (3) three FliC/TrxA-peptide fusion proteins bound to the same fragment of approximately 140 kDa of the HepG2 cell lysate (Fig. 6) .
Discussion
Targeting specific binding ligands on tumor cells is an efficient way to improve early cancer diagnosis schemes and therapy. It has been reported that cancer cells often display high levels of certain cell surface molecules, such as tumor-associated antigens or tumor-specific antigens, that are sparse on normal tissues, representing potential sites for delivery of toxic agents [13, 14] . Therefore, we carried out subtract-screening based on the FliTrx bacterial peptide library to search for HepG2 cell-specific peptides. As HepG2 is a human hepatoma cell line derived from hepatic neoplasia, which still retains numerous cellular functions typical of differentiated, normal hepatocytes (such as synthesis of albumin, transferring, α1-antitrypsin, fibrinogen, and certain other coagulation factors), it is widely accepted as a valuable and informative model system for studying human hepatocyte function [15, 16] .
Phage display libraries have been applied in ligand selections using cultured cells, animals [17] , or human patients [18] , yielding peptides specific for cell surface markers [19] . The principal advantage of display library methodologies is that selection can be carried out in a nativelike, membrane-bound environment without prior knowledge of the target cell receptors [20] . Peptide ligands generated using this method have been proved useful in tumor diagnosis and target therapy [21, 22] . The FliTrx system has been widely used as a novel bacterial displayed peptide library for studying protein-protein interactions involved in receptor-ligand binding, enzyme-substrate specificity, and antibody-antigen recognition [8, 23] .
Cell surface proteins are frequently post-translationally modified, including malignancy-specific modifications. Thus, peptides selected against purified recombinant protein might not be able to access their targets on living cells [24, 25] . Here, for the first time, we described successful living cell biopanning with this particular bacterial library. The data proved that positive clones specific for HepG2 were fully enriched after subtract screening and three HepG2-specific clones were selected from the peptide library.
Although it is possible to screen peptide libraries to select peptidic ligands that bind to previously uncharacterized molecules on the cell surface, a problem in this approach is the risk of selecting clones that bind a whole population of cell surface molecules, not the target molecule alone. To enhance the selection of specific ligands from the phagedisplayed peptide library, subtractive approaches have been applied to eliminate potential selection of clones that bind to irrelevant surface molecules [26−28] . In this case, we chose the normal liver cell line L02 as the negative control and after five subtract-screening rounds we obtained 200 clones containing the full-sized fusion from 700 random clones. Of these, 10 clones showed obviously higher affinity with HepG2 than with L02. Finally, seven different sequences were identified on account of repeated cases. We carried out not first sequencing of all random clones picked up from recovered bacteria, but bacterial PCR for identification of correct construction of fusion regions after bioscreening. The results proved that, with even the obvious enrichment of bacteria specifically binding to HepG2, only 28% of clones containing full-size inserts could be used for further binding ability assay. And only 5% of the clones appeared to bind more effectively than the others, and were able to bind specifically to hepatoma cells. Such a low positive rate was not what we aimed for and the evidence revealed the meaning of identification of binding ability of selected clones for deletion of non-specific peptides and avoidance of blind random sequencing.
The analysis of amino acid sequences in clones initially indicated some consensus groups, such as VA, EL, RI, AP, S-S, L-E, and W-E, shared by individual clones. However, after subsequent sequenced BLASTS in various protein databases, including SwissProt, PubMed, and EMBL databases, these peptides turned out to be different from any hepatocellular-specific antigens or any other peptide or protein sequences available. Further flow cytometry assays distinguished three clones that showed obviously higher affinity with HepG2 cells compared with other tumor cell lines. They were named Hep1, Hep2, and Hep3, and they could also bind to another liver carcinoma cell line SMMC7721, although the affinity was lower compared with HepG2.
Screening of protein databases allows determination of proteins with homologies to selected peptide sequences. In that event, the matched proteins are biologically relevant (can theoretically serve as ligands for the target molecules). But, in our experiment, the consensus sequence of the selected peptides did not bear any obvious similarity to the sequence of any characterized protein in the databases. It is very possible that the selected peptides mimic a complex binding epitope of potential ligands and, thus, cannot be found in databases [29] . Therefore, we tried to investigate the characteristics and gather biological information about these HepG2-specific peptides.
Variation in the FliTrx loop epitope sequence, the location of the linear epitope sequence, and the non-epitope sequence composition indicated that some different amino acid sequences are recognized by the same HepG2 cells. Bioinformatics analysis and prediction of the secondary structures of peptides and tertiary structures of TrxApeptide fusion proteins suggested that: (1) three peptides isolated from the FliTrx library were constrained in the fusion region, and formed different 3-D structures sticking out of the fusion protein, which benefit their interaction with molecules; (2) the structure of Hep3 was influenced by TrxA, however, the secondary and tertiary structures of Hep1 and Hep2 showed no significant difference; and (3) the structure character might be more important for peptide function and recognition than the sequence of peptides. We propose, therefore, that the 3-D structural model of TrxA confirmed and guaranteed the structure of peptides and affected their affinity.
As TrxA-peptide fusion proteins are more available than the respective peptides, we attempted to verify the recognition between fusion proteins and tumor cells using Western blot analysis. We used the flagellin protein, socalled FliC/TrxA-peptide fusion proteins, to identify the tumor cell lysate. Induced bacteria were incubated with cell lysate blot and Anti-Thio positive bands were observed only on the HepG2 cell lysate. Selective binding to the same band of HepG2 cell lysate occurred by different FliC/TrxA-peptide fusion proteins but not by the negative control. These results revealed that FliC/TrxA-peptide fusion proteins recognize a certain molecule or subunit on HepG2 cells, but not TrxA or the peptide itself. Furthermore, the fragment of approximately 140 kDa on HepG2 cells, which binds to fusion proteins, was also different from the other known tumor antigens, such as transferrin 95 kDa, fibrinogen 340 kDa, and α1-antitrypsin 54 kDa. The fact that several peptide consensus groups were apparent among the sequences isolated using the bacterial library suggests that these clones recognize different cell surface receptors or epitopes on whole cells [30] . However, the results suggested that different clones detected the same target molecule, implying the existence of a possible protein or subunit of approximately 140 kDa on HepG2 cells. These three peptides are not repeated sequences and their 3-D structures are not identical, but they can bind the same target molecule on tumor cells.
A protein epitope can either be continuous or discontinuous. While a continuous (also called sequential or linear) epitope is a sequential fragment from the protein sequence, a discontinuous (also called conformational) epitope is composed of several fragments scattered along the protein sequence and brought together in spatial proximity when the protein is folded [31] . Most epitopes are discontinuous, although they are often composed of small continuous elements of the sequence. Most linear epitopes of approximately five residues are involved, four residues being involved in the binding [32] , and the other replaceable residues essentially fulfilling a spacer function. E (glutamin) and L (leucine) show a high frequency among the amino acid sequences of Hep1, Hep2, and Hep3. Peptides could recognize and bind the same epitope based on the folding and reversal of the 3-D structure. Peptides selected using this methodology have moderate biological activity towards their receptor molecules on cell surfaces. This indicates that the peptides can serve as potential leads for the development of diagnostic and therapeutic agents [33] .
In summary, the development of new biological technology provides powerful methods to identify biomarkers on tumor cells or tissues, to consummate the tumor therapy methods and drugs, by specific delivery of drugs in tumor cells. A major advantage of these techniques, especially the combination-interdisciplinary method, is not affecting on innocent bystander cells. The success encountered with the bacterial peptide library with TrxAdodecapeptides suggests that the approach described in this study might be used to develop powerful and more specific peptides. Three FliC/TrxA-peptide fusion proteins selected in this study (FliC/TrxA-Hep1, FliC/TrxA-Hep2, and FliC/TrxA-Hep3) showed remarkable cell specificity of HepG2 cells. And all the facts surely pointed toward the improvement of a novel target in HepG2 cells, as there was a 140 kDa band detected by the FliC/TrxA-peptide fusion proteins. Structural bioinformatic approaches could be a helpful methodology for further investigation of target molecules on HepG2 cells and improvement of the affinity of HepG2-specific peptides.
